50 results about "Dysthymic Disorder" patented technology

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and / or improving health, nutrition, and / or another condition of a subject, and / or cognitive, learning, and / or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and / or hypertension. A kit, method, and other associated technology are also provided.

The invention belongs to the technical fields of medicaments and intermediate synthesis, and in particular relates to vitamin K3 derivatives and a preparation method thereof. The 1,4-naphthoquinone derivatives are conveniently synthesized by using 2-bromine-1,4-naphthoquinone as raw materials through one-step reaction. The vitamin K3 derivatives synthesized by the method contain vitamin K3 structures and can be used as medicaments and important synthesized intermediates. The method for preparing the vitamin K3 derivatives has the characteristics of simple operation, mild condition, low cost, high yield, and the like, has wide application prospect, and is easy for industrialized production. An IDO inhibitor synthesized by the method and containing the vitamin K3 structure can be applied to the treatment of diseases with IDO-mediated tryptophan metabolic pathway pathologic features, wherein the diseases at least comprise tumor diseases, cancers, Alzheimer, autoimmune diseases, cataracts, mood disorders, depression, and anxiety disorder.

The present invention relates generally to the fields of neuroscience, growth factors and depression. More particularly, the present invention addresses the need in the art for methods and compositions for treating neurological disorders such as depression, anxiety, panic disorder, bi-polar disorder, insomnia, obsessive compulsive disorder, dysthymic disorder and schizophrenia. In certain embodiments, the invention relates to non-covalent binding interactions between insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs).

The invention relates to a medicament for treating dysthymic disorder, which is prepared by the following raw materials, by mass, 3-10 parts of schisandra chinensis, 10-20 parts of polygala tenuifolia, 10-30 parts of radix curcumae, 10-30 parts of epimedium herb, 5-15 parts of pericarpium citri reticulatae, 5-10 parts of albizia julibrissin, 5-15 parts of cinnamon, 10-20 parts of fructus ligustrilucidi, 10-20 parts of rhizoma anemarrhenae and 10-20 parts of dogwood. By means of clinical application, the medicament for treating dysthymic disorder has the advantages of being rapid in function,obvious in treatment effect, good in tolerance, low in cost and free of any toxic and side effect.

The invention relates to a drug combination for treating dysthymic disorder.. The drug combination is prepared by uncaria, Chinese magnoliavine fruit, barbary wolfberry fruit, radix curcumae, cortex albiziae, caltrop, poria cocos, spina date seed, white paeony root, gardenia, acorus gramineus, rhizoma paridis, rhizoma gastrodiae, medofenoxate and costus root. The drug combination for treating thedysthymic disorder, disclosed by the invention, has the advantages of simpleness in component, easiness in obtaining the component, significant curative effect and no obvious side effect.

A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

The invention relates to the technical field of electronic informatization detection of biochemical indexes, and provides a regression model-based onset risk determination method for mood disorder patients. The method comprises: extracting biochemical index data of a mood disorder patient; cleaning data to obtain valid data packets; carrying out gender grouping and detection; establishing a male regression model and / or a female regression model, and carrying out regression processing to obtain an ROC curve graph and an AUC result; and finally importing the related parameters into an SPSS decision tree to obtain a male decision tree model and / or a female decision tree model. The invention also designs a system for the determination method. According to the invention, clinical biochemical indexes are subjected to data analysis through an informatization system, a multi-distance linear regression model and a decision tree model are established, accurate evaluation and risk probability prediction can be performed on patients with mental examination of MDD or BD, the diagnosis speed and accuracy of treated doctors are improved, and the prognosis of diseases is further improved.

The invention belongs to the field of drugs or health care products, and particularly relates to application of cortex periplocae C21 sterides in preparation of an IDO inhibitor. Through research, inhibition activity of periplocin A, periplocin F, periplocin U and periplocin T to IDO in cells is superior to inhibition activity of positive control drug 1-methyltryptophan (1-MF) to IDO in cells, andthe cortex periplocae C21 sterides have remarkable IDO inhibition activity, and can be used for treating cancers, an alzheimer disease, an autoimmune disease, ankylosing spondylitis, bacterial infection, cataract, mood disorder, depression or anxiety disorder.

The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereo- chemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1, having se- lective a2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are usefull for the prevention and / or treatment of central nervous system disorders, mood disorders, anxiety disorders, stress-related disorders associated with depression and / or anxiety, cognitive disorders, personality disorders, schizoaffective disorders, Parkinson's disease, dementia of the Alzheimer's type, chronic pain conditions, neurodegenerative diseases, addiction disorders, mood disorders and sexual dysfunction.

The invention belongs to the field of medicines or health products and particularly relates to phenylpropanoid glycosides and application of their pharmaceutically-acceptable derivatives in the preparation of IDO (indoleamine-2,3-dioxygenase) inhibitors. Researches herein discover that all echinacoside, pedicularioside A and pedicularioside H have better inhibitory activity against IDO in cells than that of 1-MT (1-methyl-tryptophan) against IDO in cells, have significant IDO inhibitory activity, and are suitable for treating cancers, Alzheimer's disease, ankylosing spondylitis, autoimmune diseases, bacterial infections, cataract, mood disorders, and depression or anxiety.

The invention belongs to the field of medicines or health products and particularly relates to Periploca forrestii C21 steroides in preparation of IDO (indoleamine-2,3-dioxygenase) inhibitors. Researches herein discover that both periplocoside G and periplocoside I have better intracellular IDO inhibitory activity than a positive control 1-MT (1-methyl-tryptophan), have significant IDO inhibitoryactivity, and are suitable for treating cancers, Alzheimer's disease, autoimmune diseases, ankylosing spondylitis, bacterial infections, cataract, mood disorders, and depression or anxiety.

The invention belongs to the field of medicines or health products and particularly relates to phenylpropanoid glycosides and application of their pharmaceutically-acceptable derivatives in the preparation of IDO (indoleamine-2,3-dioxygenase) inhibitors. Researches herein discover that both acteoside and cistanoside D have better inhibitory activity against IDO in cells than that of 1-MT (1-methyl-tryptophan) against IDO in cells, have significant IDO inhibitory activity, and are suitable for treating cancers, Alzheimer's disease, ankylosing spondylitis, autoimmune diseases, bacterial infections, cataract, mood disorders, and depression or anxiety.

The invention belongs to the field of drugs or health care products, and particularly relates to application of cortex periplocae C21 sterides in preparation of an IDO inhibitor. Through research, inhibition activity of periplocin C, periplocin D, periplocin O, periplocin P, periplocin Q, periplocin R, periplocin S, periplocin M and periplocin N to IDO in cells is superior to inhibition activity of positive control drug 1-methyltryptophan (1-MF) to IDO in cells, and the cortex periplocae C21 sterides have remarkable IDO inhibition activity, and can be used for treating cancers, an alzheimer disease, an autoimmune disease, ankylosing spondylitis, bacterial infection, cataract, mood disorder, depression or anxiety disorder.

The invention belongs to the field of medicines or health products and particularly relates to Periploca forrestii C21 steroides in preparation of IDO (indoleamine-2,3-dioxygenase) inhibitors. Researches herein discover that both periplocoside L and periplocoside H have better intracellular IDO inhibitory activity than a positive control 1-MT (1-methyl-tryptophan), have significant IDO inhibitoryactivity, and are suitable for treating cancers, Alzheimer's disease, autoimmune diseases, ankylosing spondylitis, bacterial infections, cataract, mood disorders, and depression or anxiety.

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

The invention relates to mixed liquor prepared from a tumor total nutrient formula. The mixed liquor is suitably taken during the recovery stage after surgery, radiotherapy, chemotherapy and hospital discharge, patients with malignant tumors have symptoms of malnutrition characterized by weight loss due to factors of tumor consumption, feeding and digestion blocking, effects of tumors on appetite and dysthymic disorder, and the patients can be supplemented with the mixed liquor. The product with the specific total-nutrient formula can provide daily needed nutrients for patients, and is especially suitable for patients with terminal cancers during the recovery stage after surgery, radiotherapy and chemotherapy in hospitals and hospital discharge.

The invention is directed to a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by administration of the compound, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, Alzheimer's disease, anxiety and addiction, the method comprising administering to a mammal, including a human, in need of such treatment a compound of formula I as described above.

The invention discloses two polymorphic substances A and B of (4-((R)-((2S,5R)-4-(3-fluorobenzyl)-(2,5-dimethylpiperazine-1-yl)(3-hydroxylbenzyl)methyl)phenyl)(4-methylpiperidine-1-yl)ketone hydrobromide; and a preparation method and an application thereof in the preparation of drugs for preventing or treating mood disorder or diseases related with a delta opioid receptor.

The present invention concerns aryl and heteroaryl substituted pyrazinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-I activity according to the general Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereo chemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, whereinthe variables are defined in Claim 1. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and / or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders; obesity; diabetes; sexual disorders and neurological disorders.